Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
The PARTNER study is a published trial protocol, not a results paper: it describes the rationale and design of a randomised crossover trial of dapagliflozin plus continuous ketone monitoring in type 1 diabetes, with no outcomes yet reported. PICO summary and expert commentary.
A small 12-week factorial feeding trial in prediabetes found that shifting unsaturated fat intake to lunch rather than dinner improved insulin-sensitivity indices, while the primary postprandial glucose outcome was null. PICO summary and expert commentary.
A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.
A single-centre Korean pilot RCT of a physician-led digital education and remote-monitoring platform in type 2 diabetes, where both arms reached the same 3-month HbA1c and the early gain reversed once monitoring stopped. PICO summary and expert commentary.
A pooled analysis of three finerenone trials found a modest reduction in new-onset atrial fibrillation/flutter across the cardio-kidney-metabolic spectrum. PICO summary and expert commentary.
A qualitative substudy of 10 youth with type 1 diabetes and high HbA1c describing their lived experience of starting advanced hybrid closed-loop therapy. PICO summary and expert commentary.
A TrialNet post hoc analysis in 40 high-risk relatives found oral insulin favourably shifted a combined glucose and C-peptide surrogate (p=0.037), not a proven delay in diabetes onset. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.
A small single-centre randomised trial testing whether a mobile educational platform improves glycaemic control and adherence in steroid-induced diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
